Efficacy and Safety of Short Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19+
SponsorGenoss Co., Ltd.
About this trial
The objective of study is to evaluate the efficacy and safety of short duration of DAPT after GENOSS® DES Implantation in patients with coronary artery disease.
Eligibility criteria
Qualifiers
Patients of 19 and over
Patients with coronary artery disease treated with GENOSS SES
Participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written informed consent as study participants
Disqualifiers
Patients with cardiogenic shock at the time of hospitalization
Patients who are pregnant or planning to become pregnant
Patients with a life expectancy of less than 1 year
Patients participating in randomized controlled trials using other medical devices
Trial design
Treatments tested in this trial
- Not listed
Trial groups
1,000 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov